Asymmetric Synthesis of (+)-CP-99,994 and (+)-L-733,060 from Enantio­merically Pure (3S,4S)-4-(tert-Butylcarbamoyl)-4-phenyl-1-buten-3-ol

Abstract

Asymmetric syntheses of neurokinin substance P receptor antagonists (+)-CP-99,994 and (+)-L-733,060 have been accomplished starting from enantiomerically pure (3S,4S)-4-(tert-butylcarbamoyl)-4-phenyl-1-buten-3-ol.

Key words

1,2-amino alcohols - 1,2-diamines - hydroformylations - neurokinin-1 antagonists - piperidines

References and Notes

• 1a Desai MC. Lefkowitz SL. Thadeio PF. Longo KP. Snider RM. J. Med. Chem.  1992,  35:  4911 
• 1b Rosen T. Seeger TF. McLean S. Desai MC. Guarino KJ. Bryce D. Pratt K. Heym J. Chalabi PM. Windels JH. Roth RW. J. Med. Chem.  1993,  36:  3197 
• For synthesis of racemic 1, see:
• 1c Desai MC. Thadeio PF. Lefkowitz SL. Tetrahedron Lett.  1993,  34:  5831 
• 1d Chandrasekhar S. Mohanty PK. Tetrahedron Lett.  1999,  40:  5071 
• 1e Yamazaki N. Atobe M. Kibayashi C. Tetrahedron Lett.  2002,  43:  7979 
• 1f Tsuritani N. Yamada K.-I. Yoshikawa N. Shibasaki M. Chem. Lett.  2002,  276 
• 1g Huang P.-Q. Liu L.-X. Wei B.-G. Ruan Y.-P. Org. Lett.  2003,  5:  1927 
• 1h Atobe M. Yamazaki N. Kibayashi C. J. Org. Chem.  2004,  69:  5595 
• For syntheses of ent- 1 and ent- 2, see:
• 1i Lemire A. Grenon M. Pourashraf M. Charette AB. Org. Lett.  2004,  6:  3517 
• 1j Takahashi K. Nakano H. Fujita R. Tetrahedron Lett.  2005,  46:  8927 
• 2a Baker R, Harrison T, Swain CJ, and Williams BJ. inventors; Eur. Patent,  0528495A1. 
• 2b Harrison T. Williams BJ. Swain CJ. Ball RG. Bioorg. Med. Chem. Lett.  1994,  4:  2545 
• 2c Tomooka K. Nakazaki A. Nakai T. J. Am. Chem. Soc.  2000,  122:  408 
• For the synthesis of racemic 2, see:
• 2d Bhaskar G. Rao BV. Tetrahedron Lett.  2003,  44:  915 
• 2e Yoon Y.-J. Joo J.-E. Lee K.-Y. Kim Y.-H. Oh C.-Y. Ham W.-H. Tetrahedron Lett.  2005,  46:  739 
• 2f For the synthesis of 14, see: Stadler H. Bös M. Heterocycles  1999,  51:  1067 
• For the synthesis of deprotected 14, see:
• 2g Lee J. Hoang T. Lewis S. Weissman SA. Askin D. Volante RP. Reider PJ. Tetrahedron Lett.  2001,  42:  6223 
• 2h Tsai M.-R. Chen B.-F. Cheng C.-C. Chang N.-C. J. Org. Chem.  2005,  70:  1780 
• 3 For a review, see: Datar P. Srivastava S. Coutinho E. Govil G. Curr. Top. Med. Chem.  2004,  4:  75 
• 4a For a review, see: Takeuchi Y. Harayama T. J. Synth. Org. Chem., Jpn.  2001,  59:  569 
• For recent syntheses of 3 and/or 4, see:
• 4b Kobayashi S. Ueno M. Suzuki R. Ishitani H. Tetrahedron Lett.  1999,  40:  2175 
• 4c Kobayashi S. Ueno M. Suzuki R. Ishitani H. Kim H.-S. Wataya Y. J. Org. Chem.  1999,  64:  6833 
• 4d Takeuchi Y. Abe H. Harayama T. Chem. Pharm. Bull.  1999,  47:  905 
• 4e Takeuchi Y. Hattori M. Abe H. Harayama T. Synthesis  1999,  1814 
• 4f Takeuchi Y. Azuma K. Takakura K. Abe H. Harayama T. Chem. Commun.  2000,  1643 
• 4g Okitsu O. Suzuki R. Kobayashi S. Synlett  2000,  989 
• 4h Taniguchi T. Ogasawara K. Org. Lett.  2000,  2:  3193 
• 4i Takeuchi Y. Azuma K. Takakura K. Abe H. Kim H.-S. Wataya Y. Harayama T. Tetrahedron  2001,  57:  1213 
• 4j Ooi H. Urushibara A. Esumi T. Iwabuchi Y. Hatakeyama S. Org. Lett.  2001,  3:  953 
• 4k Sugiura M. Kobayashi S. Org. Lett.  2001,  3:  477 
• 4l Okitsu O. Suzuki R. Kobayashi S. J. Org. Chem.  2001,  66:  809 
• 4m Sugiura M. Hagio H. Hirabayashi R. Kobayashi S. J. Am. Chem. Soc.  2001,  123:  12510 
• 4n Huang P.-Q. Wei B.-G. Ruan Y.-P. Synlett  2003,  1663 
• 4o Katoh M. Matsune R. Nagase H. Honda T. Tetrahedron Lett.  2004,  45:  6221 
• 4p Ashoorzadeh A. Caprio V. Synlett  2005,  346 
• 4q Takeuchi Y. Oshige M. Azuma K. Abe H. Harayama T. Chem. Pharm. Bull.  2005,  53:  868 
• 5a Oshitari T. Mandai T. Synlett  2003,  2374 
• 5b

  The enantiomeric purity of 5 was determined to be >99% ee by HPLC [CHIRALCEL OD-H; hexane-i-PrOH = 9:1; λ = 220 nm; flow rate: 0.8 mL/min; t _R(5) = 6.36 min; t _R(ent-5) = 8.71 min].

• 5c

  Compound 5 was also prepared from (S)-(+)-phenylglycine. See: Denis J.-N., Correa A., Greene A. E.; J. Org. Chem.; 1991, 56: 6939; Greene and co-workers reported therein that 5 was obtained in moderate yield with complete retention of enantiomeric purity by the addition of the crude Swern-oxidation product of N-Boc phenylglycinol to a large excess of vinylmagnesium bromide. Bhaskar et al. adopted this method for the preparation of compound 5 in their synthesis of 2, [2d] whose enantiomeric purity can be estimated below 50% ee in comparison with our own data. Ham and co-workers also synthesized 2 via an oxazoline derivative starting from N-benzoyl phenylglycinol. [2e] The optical rotation of 2 was in agreement with that reported in ref. 2d. These observations clearly imply that special care is required for employing easily racemizable phenylglycinal derivatives as a source of chiron approach.

• 6 Oshitari T. Akagi R. Mandai T. Synthesis  2004,  1325 
• For preparation of 1,2-amino alcohol arrays from vinyl epoxides or 1,3-amino alcohol arrays from 4-pentene-1,3-diol carbonates via the intramolecular reaction of a nitrogen-containing nucleophile with a π-allylpalladium complex, see:
• 7a Trost BM. Sudhakar AR. J. Am. Chem. Soc.  1987,  109:  3792 
• 7b Trost BM. Sudhakar AR. J. Am. Chem. Soc.  1988,  110:  7933 
• 7c Bando T. Harayama H. Fukazawa Y. Shiro M. Fugami K. Tanaka S. Tamaru Y. J. Org. Chem.  1994,  59:  1465 
• For preparation of 1,2-diamine arrays from 5-vinyloxazol-idinones via intermolecular reaction of a nitrogen-containing nucleophile with a π-allylpalladium complex, see:
• 8a Cook GR. Shanker PS. Pararajasingham K. Angew. Chem. Int. Ed.  1999,  38:  110 
• 8b Cook GR. Sankaranarayanan S. Org. Lett.  2001,  3:  3531 
• 8c Cook GR. Yu H. Sankaranarayanan S. Shanker PS. J. Am. Chem. Soc.  2003,  125:  5115 
• 10a Dunn PJ. Häner R. Rapoport H. J. Org. Chem.  1990,  55:  5017 
• 10b Seo R. Ishizuka T. Abdel-Aziz AA.-M. Kunieda T. Tetrahedron Lett.  2001,  42:  6353 
• 10c Katahira T. Ishizuka T. Matsunaga H. Kunieda T. Tetrahedron Lett.  2001,  42:  6319 
• For recent reviews, see:
• 13a Breit B. Seiche W. Synthesis  2001,  1 
• 13b Breit B. Acc. Chem. Res.  2003,  36:  264 
• For syntheses of piperidines through Rh-catalyzed hydroformylation, see:
• 13c Ojima I. Tzamarioudaki M. Eguchi M. J. Org. Chem.  1995,  60:  7078 
• 13d Ojima I. Iula DM. Tzamarioudaki M. Tetrahedron Lett.  1998,  39:  4599 
• 13e Ojima I. Vidal ES. J. Org. Chem.  1998,  63:  7999 
• {[3,3′-di-tert-Butyl-2′-(diphenoxymethoxy)-5,5′-dimethoxybiphenyl-2-yl]oxy}dibenzo[d,f][1,3]dioxepine.
• 14a Billig E, Abatjoglou AG, and Bryant DR. inventors; U. S. Patent,  4668651. 
• 14b Billig E, Abatjoglou AG, and Bryant DR. inventors; U. S. Patent,  4769498. 
• 14c Cuny GD. Buchwald SL. J. Am. Chem. Soc.  1993,  115:  2066 

9

In our preliminary investigation, DMSO was proven to be more effective solvent than toluene, THF and DMF. In addition, we found that DBU, soluble in above solvents, was much superior to other bases such as NaH, t-BuOK and Cs₂CO₃.

11

The reaction under heating at refluxing temperature in a flask overnight provided 4-phenyl-4-(3-aminopropion-amido)-3-tosylamino-1-butene as the sole product.

12

After removal of ethylenediamine in vacuo, a mixture of the mono-N-Ts-protected 1,2-diamine and 2-imidazolidone was afforded, which was subjected to the next step without further purification.

15

Five-membered N-Boc-enamide (2%) and five-membered N-Boc-aminals (5%) were also isolated after the treatment with CSA. N-Ts-enamide and N-Ts-aminals were not obtained at all.

16

Compound 10: colorless foam; [α]_D ²² -206.0 (c = 1.00, CHCl₃). ¹H NMR (CDCl₃): δ = 1.21 (br s, 6.3 H), 1.41 (br s, 2.7 H), 1.77-1.85 (m, 1 H), 1.89-2.10 (br m, 1 H), 2.45 (s, 3 H), 3.87 (m, 1 H), 3.97 (d, J = 10.1 Hz, 1 H), 4.71 (br, 0.3 H), 4.78 (br, 0.7 H), 4.98 (br, 0.7 H), 5.15 (br, 0.3 H), 6.89-7.22 (m, 2 H), 7.28-7.38 (m, 5 H), 7.78 (m, 2 H). ¹³C NMR (CDCl₃): δ = 21.6, 25.5, 26.1, 27.9, 28.2, 49.8, 57.5, 58.9, 77.2, 81.3, 81.5, 101.0, 126.2, 126.6, 127.0, 128.0, 128.5, 129.9, 137.3, 137.7, 138.1, 143.7, 152.1. Anal. Calcd for C₂₃H₂₈N₂O₄S: C, 64.46; H, 6.59; N, 6.54. Found: C, 64.37; H, 6.71; N, 6.54.

17

In the absence of TBAI, the N-alkylation was very slow at 0 °C. Compound 12, however, was afforded in 81% yield at r.t. in 5 h with the significant loss of enantiomeric purity (77% ee), which was probably caused by the elimination-addition sequence of the N-2-methoxybenzyl-tert-butyl carbamoyl group.

18

Compound 12: colorless foam; [α]_D ²¹ -105.2 (c = 1.32, CHCl₃). ¹H NMR (CDCl₃): δ = 1.19-1.70 (m, 21 H), 1.85 (br m, 1 H), 3.14 (br m, 1 H), 3.33 (br m, 1 H), 3.65 (s, 3 H), 3.75 (br m, 0.45 H), 3.99-4.10 (m, 1.65 H), 4.25 (br m, 0.45 H), 4.50 (br m, 0.45 H), 5.45 (br s, 0.9 H), 5.64 (br s, 0.1 H), 6.71 (m, 1 H), 6.86 (m, 1 H), 7.03 (m, 1 H), 7.12 (m, 1 H), 7.37-7.25 (m, 5 H). ¹³C NMR (CDCl₃): δ = 22.4, 24.6, 28.2, 41.0, 41.6, 42.1, 55.1, 56.2, 57.0, 57.5, 77.2, 79.6, 109.8, 120.2, 126.4, 127.0, 128.0, 128.4, 140.2, 141.2, 155.9. Anal. Calcd for C₂₉H₄₀N₂O₅: C, 70.13; H, 8.12; N, 5.64. Found: C, 69.90; H, 8.28; N, 5.54. The enantiomeric purity of 12 was determined to be >99% ee by HPLC [CHIRALCEL OD; hexane-i-PrOH = 30:1; λ = 220 nm; flow rate: 1.0 mL/min; t _R(12) = 6.8 min; t _R(ent-12) = 11.0 min].

19

(+)-CP-99,994 (1): ¹H NMR (free base, CDCl₃): δ = 1.40 (br d, J = 13.2 Hz, 1 H), 1.60 (m, 1 H), 1.76 (br s, 2 H), 1.93 (m, 1 H), 2.14 (br d, J = 13.1 Hz, 1 H), 2.76-2.83 (m, 2 H), 3.27 (m, 1 H), 3.41 (d, J = 13.8 Hz, 1 H), 3.44 (s, 3 H), 3.67 (d, J = 13.8 Hz, 1 H), 3.88 (d, J = 2.1 Hz, 1 H), 6.68 (br d, J = 8.2 Hz, 1 H), 6.80 (br t, J = 7.3 Hz, 1 H), 6.97 (dd, J = 1.5, 7.3 Hz, 1 H), 7.15 (dt, J = 1.5, 8.2 Hz, 1 H), 7.20-7.31 (m, 5 H). ¹³C NMR (free base, CDCl₃): δ = 20.4, 28.2, 46.7, 47.8, 54.7, 54.8, 64.0, 109.8, 120.0, 126.3, 126.5, 127.8, 128.2, 129.6, 142.4, 157.6.

20

Protection of C3-hydroxyl group as a benzoate was of choice for the subsequent hydroformylation.

21

Compound 13: colorless viscous oil; [α]_D ²⁴ -152.3 (c = 1.02, CHCl₃). ¹H NMR (CDCl₃): δ = 1.25 (br s, 6 H), 1.40-1.55 (br m, 3 H), 2.05-2.25 (m, 1 H), 2.40 (m, 1 H), 4.83 (br m, 0.33 H), 4.93 (br m, 0.67 H), 5.40 (br m, 0.33 H), 5.46-5.63 (m, 1.67 H), 7.00-7.35 (m, 6 H), 7.40 (m, 2 H), 7.55 (m, 1 H), 7.90 (m, 2 H). ¹³C NMR (CDCl₃): δ = 23.7, 24.0, 27.9, 28.2, 56.0, 57.3, 69.2, 81.3, 100.4, 126.1, 126.4, 127.5, 127.6, 128.0, 128.35, 128.38, 129.69, 129.71, 129.8, 133.1, 138.6, 152.3, 165.6. Anal. Calcd for C₂₃H₂₅NO₄: C, 72.80; H, 6.64; N, 3.69. Found: C, 72.76; H, 6.84; N, 3.66.

22

Five-membered aminals (4%) were also isolated.

23

Compound 14: colorless viscous oil; [α]_D ²² +56.7 (c = 1.3, CHCl₃) {Lit. [1g] [α]_D ¹⁵ +53.77 (c = 1.0, CHCl₃); Lit. [2d] [α]_D ²⁵ +38.30 (c = 1.92, CHCl₃)}. ¹H NMR (CDCl₃): δ = 1.37 (s, 9 H), 1.54-1.62 (m, 1 H), 1.69 (m, 1 H), 1.76-1.87 (m, 3 H), 3.04 (m, 1 H), 4.01 (dd, J = 5.8, 12.8 Hz, 1 H), 4.09 (m, 1 H), 5.32 (d, J = 5.8 Hz, 1 H), 7.27 (m, 1 H), 7.37-7.32 (m, 2 H), 7.45 (m, 2 H). ¹³C NMR (CDCl₃): δ = 23.1, 27.7, 28.3, 39.5, 59.3, 70.1, 79.9, 127.2, 128.4, 138.5, 155.4. Anal. Calcd for C₁₆H₂₃NO₃: C, 69.29; H, 8.36; N, 5.05. Found: C, 69.21; H, 8.59; N, 4.77. The enantiomeric purity of 14 was determined to be >99% ee by HPLC [CHIRALCEL OJ-H; hexane-i-PrOH = 9:1; λ = 220 nm; flow rate: 1.0 mL/min; t _R(14) = 4.80 min; t _R(ent-14) = 5.75 min].

24

Compound 15: colorless oil; [α]_D ²³ +43.3 (c = 1.60, CHCl₃) {Lit. [1g] [α]_D ²⁸ +36.90 (c = 1.0, CHCl₃)}. ¹H NMR (CDCl₃): δ = 1.46 (s, 9 H), 1.58-1.76 (m, 2 H), 1.94-2.05 (m, 2 H), 2.77 (ddd, J = 3.3, 13.4, 13.4 Hz, 1 H), 3.88 (m, 1 H), 3.95 (dd, J = 3.3, 13.4 Hz, 1 H), 4.71 (d, J = 12.5 Hz, 1 H), 4.75 (d, J = 12.5 Hz, 1 H), 5.70 (br s, 1 H), 7.25-7.36 (m, 3 H), 7.54 (br s, 1 H), 7.56 (br s, 1 H), 7.71 (br s, 2 H), 7.78 (br s, 1 H). ¹³C NMR (CDCl₃): δ = 24.2, 25.8, 28.4, 39.2, 55.4, 69.1, 78.7, 80.1, 121.4 (m), 123.3 (q, J = 272 Hz), 127.0, 127.2, 128.28, 128.32, 131.6 (q, J = 32.9 Hz), 138.0, 141.0, 155.3. The enantiomeric purity of 15 was determined to be >99% ee by HPLC [CHIRALPAK IA; hexane-i-PrOH = 30:1; λ = 220 nm; flow rate: 0.3 mL/min; t _R(15)= 14.1 min; t _R(ent- 15) = 16.6 min)].

25

L-733,060 (2): ¹H NMR (free base, CDCl₃): δ = 1.53 (m, 1 H), 1.66-1.75 (m, 1 H), 1.88 (m, 1 H), 2.22 (br d, J = 14.0 Hz, 1 H), 2.85 (ddd, J = 3.1, 12.5, 12.5 Hz, 1 H), 3.29 (m, 1 H), 3.68 (br m, 1 H), 3.85 (d, J = 1.2 Hz, 1 H), 4.13 (d, J = 12.5 Hz, 1 H), 4.52 (d, J = 12.5 Hz, 1 H), 7.25-7.29 (m, 1 H), 7.30-7.35 (m, 2 H), 7.35-7.39 (m, 2 H), 7.44 (br s, 2 H), 7.69 (br s, 1 H). ¹³C NMR (free base, CDCl₃): δ = 20.5, 28.4, 47.1, 64.2, 70.0, 77.3, 121.1 (hept, J = 4.1 Hz), 123.2 (q, J = 271 Hz), 126.7, 127.0, 127.4 (m), 128.1, 131.2 (q, J = 32.9 Hz), 141.2, 141.9.